BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 32620459)

  • 1. Prostate imaging: Contribution of PET PSMA and MRI.
    Abecassis JP; Ghazzar N; Peyromaure M; Giraud P
    Cancer Radiother; 2020 Aug; 24(5):423-428. PubMed ID: 32620459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
    Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
    Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positron-emission tomography-guided radiation therapy: Ongoing projects and future hopes.
    Giraud N; Popinat G; Regaieg H; Tonnelet D; Vera P
    Cancer Radiother; 2020 Aug; 24(5):437-443. PubMed ID: 32247689
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging of Prostate Cancer Using
    Singh A; Kulkarni HR; Baum RP
    PET Clin; 2017 Apr; 12(2):193-203. PubMed ID: 28267453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
    Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
    BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (11)C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer.
    Garcia JR; Romera N; Cozar M; Soler M; Moragas M; Escobar M
    Actas Urol Esp; 2015 May; 39(4):259-63. PubMed ID: 25454265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated
    Lütje S; Cohnen J; Gomez B; Grüneisen J; Sawicki L; Rübben H; Bockisch A; Umutlu L; Pöppel TD; Wetter A
    Nuklearmedizin; 2017 Jun; 56(3):73-81. PubMed ID: 28401244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Place of molecular imaging in the management of prostate cancer].
    Rousseau C; Le Thiec M; Maucherat B; Frindel M; Fleury V
    Cancer Radiother; 2021 Oct; 25(6-7):663-666. PubMed ID: 34404605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.
    Arsenault F; Beauregard JM; Pouliot F
    Curr Opin Support Palliat Care; 2018 Sep; 12(3):359-365. PubMed ID: 29939893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, Predictive Factors, and Prediction Nomograms for
    Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
    Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-Choline PET/MRI: The Additional Value of PET for MRI-Guided Transrectal Prostate Biopsies.
    Piert M; Montgomery J; Kunju LP; Siddiqui J; Rogers V; Rajendiran T; Johnson TD; Shao X; Davenport MS
    J Nucl Med; 2016 Jul; 57(7):1065-70. PubMed ID: 26985061
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Kanoun S; Walker P; Vrigneaud JM; Depardon E; Barbier V; Humbert O; Moulin M; Créhange G; Cormier L; Loffroy R; Brunotte F; Cochet A
    Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):986-994. PubMed ID: 28333020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical perspectives of PSMA PET/MRI for prostate cancer.
    Barbosa FG; Queiroz MA; Nunes RF; Marin JFG; Buchpiguel CA; Cerri GG
    Clinics (Sao Paulo); 2018 Sep; 73(suppl 1):e586s. PubMed ID: 30281701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer.
    Hoffmann MA; Wieler HJ; Baues C; Kuntz NJ; Richardsen I; Schreckenberger M
    Urology; 2019 Aug; 130():1-12. PubMed ID: 30986486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early
    Domachevsky L; Bernstine H; Goldberg N; Nidam M; Stern D; Sosna J; Groshar D
    Clin Radiol; 2017 Nov; 72(11):944-950. PubMed ID: 28716214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PSMA PET and Radionuclide Therapy in Prostate Cancer.
    Bouchelouche K; Turkbey B; Choyke PL
    Semin Nucl Med; 2016 Nov; 46(6):522-535. PubMed ID: 27825432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT.
    Bluemel C; Krebs M; Polat B; Linke F; Eiber M; Samnick S; Lapa C; Lassmann M; Riedmiller H; Czernin J; Rubello D; Bley T; Kropf S; Wester HJ; Buck AK; Herrmann K
    Clin Nucl Med; 2016 Jul; 41(7):515-21. PubMed ID: 26975008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New aspects of molecular imaging in prostate cancer.
    Ceci F; Castellucci P; Cerci JJ; Fanti S
    Methods; 2017 Nov; 130():36-41. PubMed ID: 28711565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.